barclays ups bluebird rating to overweight citing sickle cell opportunity.

barclays upgrades bluebird bio (blue). fintel reports that on june 1 2023 barclays upgraded their outlook for bluebird bio (nasdaq:blue) from equal-weight to overweight .

bluebird (blue) posts q1 earnings focuses on zynteglo skysona. bluebird bio blue reported revenues of $2.4 million in the first quarter up from $1.9 million in the year-ago quarter. revenues missed the zacks consensus estimate of $20 m

bluebird bio files for $350m mixed shelf offering.

bluebird bio surges 14% on q1 results sickle cell candidate.

bluebird bio (blue) q1 earnings surpass estimates. bluebird bio (blue) came out with quarterly earnings of $0.21 per share beating the zacks consensus estimate of a loss of $0.54 per share. this compares to loss of $1.66 per share a ye

bluebird bio (blue) may report negative earnings: know the trend ahead of next weeks release. the market expects bluebird bio (blue) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the qu

with fda submission for sickle cell gene therapy bluebird bio can potentially have 3 approved products by 2023. ) has submitted its biologics license application (bla) to the fda seeking approval for lovotibeglogene autotemcel (lovo-cel) gene therapy in

bluebird bio submits us marketing application for blood disorder gene therapy. bluebird bio inc said on monday it has submitted a marketing application to the United States food and drug administration for its gene therapy to treat sickle cell d

bluebird submits us marketing application for blood disorder gene therapy. bluebird bio said on monday it has submitted a marketing application to the United States food and drug administration for its gene therapy to treat sickle cell disease a